Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Primary objective - to determine the 6-month progression free survival (PFS) of adult
patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly
temozolomide plus (Avastin) bevacizumab.
Secondary objectives - to determine radiographic response including specialized MRI
sequences, safety and overall survival of adult patients with with recurrent glioblastoma
multiforme/gliosarcoma treated with bi-weekly temozolomide plus bevacizumab (Avastin).
Additionally, tumor DNA (MGMT) analysis as it relates to survival will be evaluated.